Recently, at the 2026 Zhongguancun Forum “Global IP Protection and Innovation”, the Haidian District Market Supervision Administration of Beijing officially released the “Guidelines for Intellectual Property Protection in AI New Drug R&D Industry” (hereinafter referred to as the Guidelines), providing a systematic solution for building a solid intellectual property protection basis for this strategically important emerging industry.
Based on the realities of the industry, the Guidelines focus on the pain points and difficulties in the entire chain of intellectual property protection for AI new drug discovery, offering detailed references from four key dimensions, such as optimizing portfolios in diversified way, strengthening protection in full-process, reducing costs in enforcing rights, and building robust defense to prevent risks. (Apr. 7, 2026, IPRdaily)
Based on the realities of the industry, the Guidelines focus on the pain points and difficulties in the entire chain of intellectual property protection for AI new drug discovery, offering detailed references from four key dimensions, such as optimizing portfolios in diversified way, strengthening protection in full-process, reducing costs in enforcing rights, and building robust defense to prevent risks. (Apr. 7, 2026, IPRdaily)